Upstream Bio, Inc.
UPBAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 11, 2026 | Truist Financial | $25.00(+253%) | $7.09 | TheFly | |
| Mar 27, 2026 | Evercore ISI | $15.00(+73%) | $8.67 | TheFly | |
| Dec 17, 2025 | Mizuho Securities | Joseph Catanzaro | $51.00(+80%) | $28.33 | TheFly |
| Oct 14, 2025 | Truist Financial | $47.00(+134%) | $20.08 | TheFly | |
| Nov 5, 2024 | Piper Sandler | Yasmeen Rahimi | $75.00(+168%) | $28.02 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 2, 2026 |
| JP Morgan | maintain | Neutral | Aug 14, 2026 |
| Truist Securities | maintain | Buy | Aug 12, 2026 |
| JP Morgan | downgrade | Overweight →Neutral | Jun 12, 2026 |
| Mizuho | maintain | Outperform | May 14, 2026 |
| Evercore ISI Group | downgrade | Outperform →In Line | Mar 27, 2026 |
Earnings History
Next report: Mar 17, 2027 · EPS est. $-0.73| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 11, 2026 | $-0.73 | $-0.78 | $773.0K | $431.1K |
| May 13, 2026 | $-0.75 | $-0.75 | $1.0M | $1.0M |
| Mar 26, 2026 | $-0.79 | $-0.73 | $668.0K | $584.0K |
| Nov 5, 2025 | $-0.63 | $-0.78 | $683.0K | $521.6K |
| Aug 6, 2025 | $-0.74 | $-0.61 | $937.0K | $317.0K |
| May 6, 2025 | $-0.51 | $-0.49 | $566.0K | $317.0K |
| Mar 12, 2025 | $-0.41 | $-0.56 | $613.0K | $384.8K |
| Nov 7, 2024 | $-6.96 | $-0.54 | $607.0K | $397.3K |
News
Keros Therapeutics (NASDAQ: KROS - Get Free Report) and Upstream Bio (NASDAQ: UPB - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation. Volatility and Risk Keros Therapeutics has a
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma – – Verekitug also delivered clinically meaningful improvements in lung function (FEV 1 ) and exhaled nitric oxide (FeNO) with every 12-week dosing – – The Company remains on track to initiate Phase 3 trials in severe asthma and CRSwNP in Q1 2027 , designed to deliver best-in-class efficacy in both indications by evaluating a 400 mg quarterly regimen of verekitug in broad patient popu…
– Following productive FDA discussions, Upstream Bio will study 400 mg of verekitug administered every 12 weeks, versus placebo, in severe asthma and CRSwNP with one pivotal Phase 3 trial in each indication – – The Company's Phase 3 strategy is designed to deliver best-in-class efficacy across both indications by evaluating a high-dose, quarterly regimen of verekitug in broad patient populations – – The Company remains on track to initiate both Phase 3 trials in Q1 2027 – WALTHAM, Mass., Sept. 0…
Fannie Mae Announces Sale of Non-Performing Loans PR Newswire WASHINGTON, Aug. 19, 2026
Upstream Bio, Inc. (UPB) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $0.74 per share a year ago.